These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88. Pepticinnamins, new farnesyl-protein transferase inhibitors produced by an actinomycete. II. Structural elucidation of pepticinnamin E. Shiomi K; Yang H; Inokoshi J; Van der Pyl D; Nakagawa A; Takeshima H; Omura S J Antibiot (Tokyo); 1993 Feb; 46(2):229-34. PubMed ID: 8468236 [TBL] [Abstract][Full Text] [Related]
89. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines. Mazzocca A; Giusti S; Hamilton AD; Sebti SM; Pantaleo P; Carloni V Mol Pharmacol; 2003 Jan; 63(1):159-66. PubMed ID: 12488548 [TBL] [Abstract][Full Text] [Related]
90. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604 [TBL] [Abstract][Full Text] [Related]
92. Inhibitors of Ras farnesyltransferases. Tamanoi F Trends Biochem Sci; 1993 Sep; 18(9):349-53. PubMed ID: 8236454 [TBL] [Abstract][Full Text] [Related]
93. RhoB and the cellular response to farnesyltransferase inhibitors: the search for clues to cell death mechanisms. Bernhard EJ Cancer Biol Ther; 2003; 2(3):281-2. PubMed ID: 12878866 [No Abstract] [Full Text] [Related]
95. Hydrophobicity and functionality maps of farnesyltransferase. Ahmed S; Majeux N; Caflisch A J Mol Graph Model; 2001; 19(3-4):307-17, 380-7. PubMed ID: 11449569 [TBL] [Abstract][Full Text] [Related]
96. Farnesyltransferase inhibition: a novel method of immunomodulation. Si MS; Ji P; Tromberg BJ; Lee M; Kwok J; Ng SC; Imagawa DK Int Immunopharmacol; 2003 Apr; 3(4):475-83. PubMed ID: 12689653 [TBL] [Abstract][Full Text] [Related]
97. Assays for inhibitors of CAAX farnesyltransferase in vitro and in intact cells. James GL; Brown MS; Goldstein JL Methods Enzymol; 1995; 255():38-46. PubMed ID: 8524124 [No Abstract] [Full Text] [Related]
98. Synthesis and screening of a CaaL peptide library versus FTase reveals a surprising number of substrates. Krzysiak AJ; Aditya AV; Hougland JL; Fierke CA; Gibbs RA Bioorg Med Chem Lett; 2010 Jan; 20(2):767-70. PubMed ID: 20005705 [TBL] [Abstract][Full Text] [Related]
99. An evolutionary approach for structure-based design of natural and non-natural peptidic ligands. Budin N; Ahmed S; Majeux N; Caflisch A Comb Chem High Throughput Screen; 2001 Dec; 4(8):661-73. PubMed ID: 11812261 [TBL] [Abstract][Full Text] [Related]
100. Structure-Guided Discovery of Potent Antifungals that Prevent Ras Signaling by Inhibiting Protein Farnesyltransferase. Wang Y; Xu F; Nichols CB; Shi Y; Hellinga HW; Alspaugh JA; Distefano MD; Beese LS J Med Chem; 2022 Oct; 65(20):13753-13770. PubMed ID: 36218371 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]